Related Experiment Videos
The evolving management of migraine.
Avi Ashkenazi1, Stephen D Silberstein
1Jefferson Headache Center, Department of Neurology, Thomas Jefferson University Hospital, Gibbon Building, Suite #8130, 111 South Eleventh Street, Philadelphia, PA 19107, USA.
Current Opinion in Neurology
|July 15, 2003
Summary
Recent migraine drug advancements offer improved acute and preventive treatment options. New triptans, droperidol, botulinum toxin, topiramate, and candesartan provide more flexible and tolerable therapeutic plans for migraineurs.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine treatment landscape is evolving.
- Need for diverse and effective therapeutic strategies.
Purpose of the Study:
- Review recent advances in acute and preventive migraine therapies.
- Highlight new drug developments and their clinical utility.
Main Methods:
- Literature review of recent studies on migraine pharmacotherapy.
- Analysis of novel drug formulations and their efficacy.
Main Results:
- New triptans (frovatriptan, eletriptan) and zolmitriptan nasal spray offer improved acute treatment options.
- Droperidol shows efficacy for acute attacks but requires monitoring.
- Botulinum toxin type A, topiramate, and candesartan demonstrate promise for migraine prevention with varying benefits and side effect profiles.
Conclusions:
- Emerging pharmacological agents expand treatment spectrum for both acute and preventive migraine management.
- Increased flexibility and tolerability in treatment plans are now achievable.